(ERF) Eurofins Scientific SE - Ratings and Ratios

Exchange: PA • Country: Luxembourg • Currency: EUR • Type: Common Stock • ISIN: FR0014000MR3

ERF: Testing, Certification, Laboratory, Analytical, Services, Diagnostics

Eurofins Scientific SE (PA:ERF) stands as a leader in the global analytical testing and laboratory services sector, renowned for its comprehensive suite of services designed to ensure the safety, quality, and regulatory compliance of products across diverse industries. Established in 1987 and headquartered in Luxembourg, the company has carved a niche through its extensive

Additional Sources for ERF Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ERF Stock Overview

Market Cap in USD 9,508m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Biotechnology
IPO / Inception

ERF Stock Ratings

Growth 5y -23.1%
Fundamental 40.8%
Dividend 14.7%
Rel. Strength Industry -13.4
Analysts -
Fair Price Momentum 46.77 EUR
Fair Price DCF 127.87 EUR

ERF Dividends

Dividend Yield 12m 0.99%
Yield on Cost 5y 1.14%
Annual Growth 5y -7.40%
Payout Consistency 76.4%

ERF Growth Ratios

Growth Correlation 3m 71.9%
Growth Correlation 12m -64.8%
Growth Correlation 5y -45.8%
CAGR 5y 2.04%
CAGR/Max DD 5y 0.03
Sharpe Ratio 12m -0.28
Alpha -12.86
Beta -0.14
Volatility 33.24%
Current Volume 347.2k
Average Volume 20d 385.7k
What is the price of ERF stocks?
As of February 22, 2025, the stock is trading at EUR 48.80 with a total of 347,239 shares traded.
Over the past week, the price has changed by -2.18%, over one month by +1.20%, over three months by +5.26% and over the past year by -14.02%.
Is Eurofins Scientific SE a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Eurofins Scientific SE (PA:ERF) is currently (February 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 40.82 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ERF as of February 2025 is 46.77. This means that ERF is currently overvalued and has a potential downside of -4.16%.
Is ERF a buy, sell or hold?
Eurofins Scientific SE has no consensus analysts rating.
What are the forecast for ERF stock price target?
According to ValueRays Forecast Model, ERF Eurofins Scientific SE will be worth about 50.5 in February 2026. The stock is currently trading at 48.80. This means that the stock has a potential upside of +3.52%.
Issuer Forecast Upside
Wallstreet Target Price 58.4 19.7%
Analysts Target Price - -
ValueRay Target Price 50.5 3.5%